NCT04435964View on ClinicalTrials.gov

Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment

CompletedOBSERVATIONAL
Enrollment

247

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
MelanomaLung CancerHead and Neck CancerUrogenital NeoplasmsBreast Cancer
Interventions
DRUG

Immunotherapy

Patients treated as per clinical prescription with immunocheckpoint inhibitors (ICI) irrespective of treatment schedule, either as single agent or in combination with chemotherapy and/or radiotherapy

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

St Vincent's University Hospital, Ireland

OTHER

collaborator

Oslo University Hospital

OTHER

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT04435964 - Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment | Biotech Hunter | Biotech Hunter